van den Berk-Smeekens, Iris http://orcid.org/0000-0002-9607-1537
de Korte, Manon W. P. http://orcid.org/0000-0001-9553-1979
van Dongen-Boomsma, Martine http://orcid.org/0000-0003-2666-5556
Oosterling, Iris J.
den Boer, Jenny C.
Barakova, Emilia I. http://orcid.org/0000-0001-5688-4878
Lourens, Tino
Glennon, Jeffrey C. http://orcid.org/0000-0002-2371-0422
Staal, Wouter G. http://orcid.org/0000-0002-3276-1133
Buitelaar, Jan K. http://orcid.org/0000-0001-8288-7757
Funding for this research was provided by:
ZonMw (project number 95103010)
Innovative Medicines Initiative (Joint Undertaking Grant No. 115300)
Karakter
Article History
Received: 27 November 2020
Accepted: 15 May 2021
First Online: 3 June 2021
Declarations
:
: Jan K Buitelaar has been in the past 3 years a consultant to / member of the advisory board of / and/or speaker for Shire, Roche, Medice, Novartis and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, and royalties. Iris van den Berk-Smeekens, Manon W.P. de Korte, Martine van Dongen-Boomsma, Iris J. Oosterling, Jenny C. den Boer, Emilia I. Barakova, Tino Lourens, Jeffrey C. Glennon, and Wouter G. Staal declare no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from the parents of all participants included in the study.
: Parents of all participants signed informed consent regarding publishing their data.